We are live on ! Find out more
BCLI

BRAINSTORM CELL THERAPUTC
BCLI

Delisted

BCLI was delisted on the 17th of July, 2025.

Back to rankings

38 hedge funds and large institutions have $2.52M invested in BRAINSTORM CELL THERAPUTC in 2024 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 4 increasing their positions, 10 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

45% more call options, than puts

Call options by funds: $42K | Put options by funds: $29K

0.25% less ownership

Funds ownership: 1.16% → 0.92% (-0.25%)

21% less funds holding

Funds holding: 48 → 38 (-10)

38% less capital invested

Capital invested by funds: $4.09M → $2.52M (-$1.57M)

60% less repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 10

64% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 14

Holders
38
Holders Change
-10
Holders Change %
-20.83%
% of All Funds
0.55%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
4
Reduced
10
Closed
14
Calls
$42K
Puts
$29K
Net Calls
+$13K
Net Calls Change
-$16K

Top Buyers

Rank Fund Capital Flow
1
Geode Capital Management
Geode Capital Management
Massachusetts
+$62.5K
2
XT
XTX Topco
Cayman Islands
+$16.7K
3
Wells Fargo
Wells Fargo
California
+$7.54K
4
Morgan Stanley
Morgan Stanley
New York
+$3.93K
5
JF
Jump Financial
Illinois
+$3.46K

Top Sellers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
-$321K
2
IC
Ikarian Capital
Texas
-$30.5K
3
TSS
Two Sigma Securities
New York
-$25.9K
4
TRCT
Tower Research Capital (TRC)
New York
-$19.9K
5
VF
Virtu Financial
New York
-$17K
Name Holding Trade Value Shares
Change 		Change in
Stake
AWM
26
Activest Wealth Management
Florida
$1.15K -$651 -138 -29%
BSB
27
Bangor Savings Bank
Maine
$921 – – –
SPIA
28
Steward Partners Investment Advisory
New York
$622 – – –
UBS Group
29
UBS Group
Switzerland
$575 -$1.45K -307 -65%
Bank of America
30
Bank of America
North Carolina
$370 +$38 +8 +8%
CA
31
Clearstead Advisors
Ohio
$346 – – –
FCM
32
Fourpath Capital Management
Oklahoma
$238 +$326 +69 New
DJSG
33
D.J. St. Germain
Massachusetts
$115 – – –
WIM
34
Westside Investment Management
California
$46 – – –
JP Morgan Chase
35
JP Morgan Chase
New York
$40 -$24 -5 -29%
Northwestern Mutual Wealth Management
36
Northwestern Mutual Wealth Management
Wisconsin
$37 – – –
BWL
37
Bogart Wealth LLC
Virginia
$8 +$9 +2 New
IC
38
Ikarian Capital
Texas
– -$30.5K -6,016 Closed
VF
39
Virtu Financial
New York
– -$17K -3,306 Closed
Jane Street
40
Jane Street
New York
– -$6.71K -1,322 Closed
PFA
41
Professional Financial Advisors
Nebraska
– -$5.85K -1,152 Closed
SA
42
Sanctuary Advisors
Indiana
– -$9.2K -1,147 Closed
FAFN
43
First Affirmative Financial Network
Colorado
– -$4.84K -953 Closed
LPL Financial
44
LPL Financial
California
– -$3.4K -670 Closed
Simplex Trading
45
Simplex Trading
Illinois
– -$1.37K -290 -79%
EWA
46
EverSource Wealth Advisors
Alabama
– -$728 -142 Closed
VAG
47
VisionPoint Advisory Group
Texas
– -$658 -130 Closed
CWM
48
Cranbrook Wealth Management
Michigan
– -$339 -67 Closed
BNP Paribas Financial Markets
49
BNP Paribas Financial Markets
France
– -$123 -24 Closed
MSFP
50
Mark Sheptoff Financial Planning
Connecticut
– -$34 -7 Closed
1
2

BCLI Hedge Fund Activity: Q3 2024 in Review

38 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in BRAINSTORM CELL THERAPUTC (BCLI) for Q3 2024, worth a combined $2.52M — down 38% from $4.09M a quarter earlier.

Sellers outnumbered buyers: 14 funds closed out of BCLI and 5 opened new positions — a net loss of 9 holders — while 10 trimmed existing stakes and 4 added.

The largest buyer was Geode Capital Management, adding an estimated $62.5K. The largest seller was Armistice Capital, cutting an estimated $321K.

  • 38 institutional investors held BRAINSTORM CELL THERAPUTC (BCLI) as of Q3 2024, down from 48 in Q2 2024.
  • Funds reported $2.52M of BRAINSTORM CELL THERAPUTC stock for Q3 2024, down 38% quarter-over-quarter.
  • 5 funds opened new BRAINSTORM CELL THERAPUTC positions in Q3 2024 and 14 closed out, a net change of -9 holders.
  • The largest BRAINSTORM CELL THERAPUTC buyer in Q3 2024 was Geode Capital Management, an estimated $62.5K added.
  • The largest BRAINSTORM CELL THERAPUTC seller in Q3 2024 was Armistice Capital, an estimated $321K sold.

Based on aggregated 13F filings for Q3 2024.